Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour activity, we conducted a combination phase I study in advanced non-small-cell lung cancer (NSCLC). Patients received nedaplatin (60–100 mg m(−2) given intravenously over 90 mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, T, Tamura, K, Yamamoto, N, Nogami, T, Satoh, T, Kaneda, H, Nakagawa, K, Fukuoka, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409510/
https://www.ncbi.nlm.nih.gov/pubmed/15150564
http://dx.doi.org/10.1038/sj.bjc.6601817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409510/
https://www.ncbi.nlm.nih.gov/pubmed/15150564
http://dx.doi.org/10.1038/sj.bjc.6601817

Ejemplares similares